Table 1.
Baseline Patient Characteristics
| Characteristic | All (%) n = 34 |
CRs (%) n = 3 |
|---|---|---|
| Median age (range), y | 56 (22–69) | 55 (47–60) |
| ECOG performance status | ||
| 0 | 30 (88) | 3 (100) |
| 1 | 4 (12) | |
| BRCA1/2 carriers | ||
| Yes | 2 (6) | |
| No | 27 (79) | 3 (100) |
| Unknown | 5 (15) | |
| Patients with de novo metastatic disease | 4 (12) | 1 (33) |
| Prior lines of metastatic chemotherapy | ||
| 0 | 20 (59) | 2 (67) |
| 1 | 14 (41) | 1 (33) |
| Prior breast cancer therapy | ||
| Taxanes | 31 (91) | 2 (67) |
| Cytoxan | 31 (91) | 2 (67) |
| Anthracyclines | 27 (79) | 2 (67) |
| Capecitabine | 8 (23) | |
| Eribulin | 4 (12) | 1 (33) |
| Immune checkpoint inhibitors | 4 (12) | |
| PARP inhibitors | 3 (9) | |
| Disease free interval < 12 monthsa | 15 (50) | 1 (33) |
| Metastatic sites | ||
| Liver | 18 (53) | 3 (100) |
| Lung | 18 (53) | 2 (67) |
| Bone | 13 (38) | 1 (33) |
| Brain | 1 (3) |
a
Percent with disease free interval < 12 months was calculated from the 30 participants without de novo metastatic disease.
CR, complete responder; ECOG, Eastern Cooperative Oncology Group; PARP, poly (ADP-ribose) polymerase